바이오테크 보도자료
-
- PTT Invests in Lotus Pharmaceutical's Strategic Partnership in South East Asia
- Lotus Pharmaceutical Co., Ltd. (“Lotus” or “the Company”, Taiwan TWSE ticker: 1795), an Alvogen company, has announced the issuance of new shares through private placement to be acquired by Innobic (Asia). The move is aimed at further strengthenin...
- 2021년 04월 20일
-
- Humanigen Reports Positive Data With Lenzilumab in the ZUMA-19 CAR-T Phase 1b Study in DLBCL and Plans to Initiate a Potential Registrational Study
- Humanigen, Inc. (Nasdaq: HGEN) (“Humanigen”), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab™, today announced positive data f...
- 2021년 04월 20일
-
- ROSALIND, HELiXrUS and Geninus Partner to Bring Powerful New Single Cell Analysis Services to Cancer Researchers
- ROSALIND®, a software leader in extracting meaningful insights from diverse pools of life science data, today announced that it has partnered with two Seoul-based technology providers to enable a powerful new Single Cell data analysis solution for...
- 2021년 04월 16일
-
- Boehringer Ingelheim and MD Anderson Expand Collaboration to Accelerate Development of KRAS and TRAILR2 Compounds in Lung Cancer
- Boehringer Ingelheim and The University of Texas MD Anderson Cancer Center today announced the extension and expansion of their joint Virtual Research and Development Center (VRDC) to explore new molecules from Boehringer Ingelheim’s KRAS (Kirsten...
- 2021년 04월 15일
-
- RubrYc Therapeutics Announces a Research Collaboration and License Option Agreement With Zai Labs
- RubrYc Therapeutics, Inc., a pre-clinical biotherapeutics company developing epitope selective therapies, today announced that it has entered into a research collaboration and license option agreement with Zai Labs, Inc. for the use of RubrYc’s Me...
- 2021년 04월 14일
-
- LintonPharm Announces Authorization from China Health Authority (NMPA) to Proceed with a Phase 1/2 Trial Evaluating Catumaxomab for the treatment of Non-Muscle Invasive Bladder Cancer
- LintonPharm Co., Ltd., a China-based clinical stage biopharmaceutical company focused on the development of T cell engaging bispecific antibodies for cancer immunotherapy, today announced that China’s health authority, National Medical Products Ad...
- 2021년 04월 14일
-
- Merck Advances ATR Inhibitor Berzosertib in Small Cell Lung Cancer With New Published Data and Initiation of Phase II Trial With Registrational Intent
- Merck, a leading science and technology company, today announced key clinical advancements for berzosertib (M6620), an investigational, potent and selective ataxia telangiectasia and Rad3-related (ATR) inhibitor. Berzosertib is the leading asset i...
- 2021년 04월 13일
-
- Diaceutics Appoints Yvanka Gilliam as Vice President of Operations, Asia Pacific
- Diaceutics PLC, (AIM: DXRX), today announces the appointment of Yvanka Gilliam as Vice President of Operations, Asia Pacific (APAC). In her new role, Yvanka will be responsible for managing business development and operations within the APAC regio...
- 2021년 04월 13일
-
- Yokogawa Selects C3 AI Suite to Enhance Enterprise AI Applications
- C3 AI (NYSE: AI) and Yokogawa Electric Corporation (TOKYO: 6841) (“Yokogawa”) today announced that Yokogawa has selected the C3 AI® Suite as a platform to enhance enterprise AI applications and complement its digital transformation solutions and s...
- 2021년 04월 13일
-
- Deargen Announces New Model of Optimizing Drug Candidate Molecules With Enhanced Performance by Nearly Double Compared to Existing Models
- Deargen, an artificial intelligence (AI)-based drug discovery and development biotech company, announced on April 9 that it presented study results on controlled molecule generator (CMG) technology at the ACM Conference on Health, Inference and Le...
- 2021년 04월 13일
-
- Humanigen Announces Positive Results From Phase 1 Study of Ifabotuzumab in Glioblastoma Multiforme
- Humanigen, Inc. (Nasdaq:HGEN), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab™, today announced positive results from the Phas...
- 2021년 04월 12일
전시회
